"instanceType","label","uuid:ID","description","rationale","name","id"
"StudyDesign","","1fa23eea-8117-4969-ba97-c1c6dcd103c2","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","StudyDesign_1"
